AT-527 Terminated Phase 2 Trials for Coronavirus Disease 2019 (COVID‑19) Treatment

Back to AT-527
IndicationsStatusPurposePhase
TerminatedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT04396106Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19) in a Hospital Setting